Kaiser Permanente’s Institute for Health Policy will bring together leaders from across sectors to learn why drug value is a critical part of the national dialouge on drug pricing.
During this meeting, participants and speakers will:
- Advance the conversation on how to define and assess drug value.
- Lift up existing and emerging policy opportunities that encourage a value-based approach to drug pricing.
|9:00 a.m.||Welcome & Opening Remarks|
|9:35 a.m||Morning Keynote|
|10:00 a.m.||Panel 1: Defining and Assessing Drug Value|
|11:10 a.m.||Mid-Morning Break|
|11:20 a.m.||Panel 2: Paying for Value|
|1:15 p.m.||Conversation with Industry|
|2:00 p.m.||Looking Forward: A Value-Based Approach to Drug Pricing|
|3:00 p.m.||Themes Emerging from Today’s Forum|
Sameer V. Awsare, MD, FACP
Sameer Awsare, MD, FACP, is an Associate Executive Director for The Permanente Medical Group in charge of pharmacy, adult and family medicine, mental health, risk adjusted coding, revenue cycle, outside medical services, pain management and the opioid initiative.
Dr. Awsare joined the Permanente Medical Group in 1993. In addition to his clinical responsibilities, he is involved in resident teaching and has served on several boards in various leadership roles. He is currently the secretary and chair of the Governance Committee of the Mid-Atlantic Permanente Medical Group Board.
Dr. Awsare is board certified in Internal Medicine. He received his bachelor’s degree and medical degree from the University of California, Irvine. He has served on the voluntary clinical faculty at the Stanford University of School of Medicine. Dr. Awsare is a fellow of the American College of Physicians.
Tony Barrueta is senior vice president of government relations for Kaiser Foundation Health Plan, Inc. in Oakland, California. He oversees development of Kaiser Permanente’s public policy positions, in collaboration with senior leadership throughout the organization, to ensure that Kaiser Permanente maintains a common voice in support of the interests of the organization, its members, and the communities it serves.
Barrueta holds a bachelor’s degree in history from Boston College and a law degree from the University of Texas at Austin.
Peter Bach, MD, MAPP
Peter Bach, MD, MAPP, is a physician, epidemiologist, researcher, and healthcare policy expert who studies U.S. pharmaceutical pricing and reimbursement policy. His work includes developing models for indication specific pricing, point of sale rebates, and subscription-based payment for drugs.
He has published more than 100 peer-reviewed articles and editorials in scientific journals such as the New England Journal of Medicine and the Journal of the American Medical Association and has been inducted into the National Academy of Medicine, the American Society for Clinical Investigation and the Johns Hopkins Society of Scholars.
Dr. Bach graduated from Harvard College, the University of Minnesota Medical School, and the Harris School for Public Policy at the University of Chicago.
Rena M. Conti, PhD
Rena M. Conti is the associate research director of Biopharma and Public Policy for the Boston University Institute for Health System Innovation and Policy. She is also an associate professor at the Boston University Questrom School of Business.
Dr. Conti ‘s research focuses on the organization, financing and regulation of medical care. She has written extensively on the pricing, demand, and supply of prescription drugs.
Previously, Dr. Conti was an associate professor of Health Economics and Policy at the University of Chicago Medical School and the Harris School of Public Policy.
Maisha Draves, MD
Maisha Draves is the medical director for Pharmacy in Northern California for The Permanente Medical Group. In this role, she collaborates with the chair of the Regional Pharmacy & Therapeutics Committee on formulary and pharmacy policy and with the Drug Information Services group on the strategies related to drug shortages and recalls. She provides oversight for pharmacy-related research and develops strategies for Kaiser Permanente Northern California’s drug utilization management efforts.
She received her medical degree from Harvard Medical School.
Sarah K. Emond, MPP
With over 20 years of experience in the business and policy of health care, Sarah Emond leads the strategic operations of the Institute for Clinical and Economic Review, a leading non-profit health policy research organization, as executive vice president and chief operating officer. She is responsible for overseeing ICER’s public programs, stakeholder engagement, and finances.
Emond speaks frequently at national conferences on the topics of prescription drug pricing policy, comparative effectiveness research, and value-based health care.
She holds a master’s degree in public policy with a concentration in health policy from the Heller School for Social Policy and Management at Brandeis University and a bachelor’s degree in biological sciences from Smith College.
Chris Leibman is senior vice president, Value and Access at Biogen in Cambridge, Massachusetts where he leads the payer evidence planning and access strategy organization globally. He joined Biogen in 2014, and until his move back to the U.S. last year, was most recently vice president of Europe and Canada Market Access and Pricing at Biogen, where he led the European/Canada regional team responsible for value, access, and pricing strategy development and execution across the Biogen portfolio.
Chris brings two decades of diverse experiences in biopharmaceutical development, commercialization, and working across multi-company alliances.
Mark E. Miller
Mark Miller leads Arnold Ventures’ work to lower the cost and improve the value of health care. He has more than 30 years of experience developing and implementing health policy, including prior positions as the executive director of Medicare Payment Advisory Commission; assistant director of Health and Human Resources at the Congressional Budget Office; deputy director of Health Plans at the Centers for Medicare and Medicaid Services; health financing branch chief at the Office of Management and Budget; and senior research associate at the Urban Institute.
Mark has extensive experience identifying emerging health care issues, developing policy solutions, working with policymakers, and engaging diverse stakeholders. He has been directly involved in the development of major health legislation such as the Balanced Budget Act; the Medicare Prescription Drug, Improvement, and Modernization Act; and the Affordable Care Act.
Mark holds a doctorate in public policy analysis from the State University of New York at Binghamton and a bachelor’s and master’s degrees in political science from Old Dominion University.
Leigh Purvis is the director of Health Services Research in AARP’s Public Policy Institute. She leads a team of policy analysts and researchers who work on health care issues that are relevant to the 50+ population.
In addition, Purvis heads the Institute’s work on prescription drug issues. Her primary areas of expertise are prescription drug pricing, biologic drugs, and prescription drug coverage under Medicare. She is also a coauthor of the Public Policy Institute’s annual Rx Price Watch reports, which track price trends for prescription drugs widely used by older Americans.